New drug PEP-010 shows promise in early cancer trial
NCT ID NCT04733027
First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times
Summary
This early-phase trial tests a new drug called PEP-010 in people with advanced solid tumors that have spread. The study checks if PEP-010 is safe alone or with chemotherapy (paclitaxel or gemcitabine). About 57 adults with metastatic pancreatic, ovarian, or other solid cancers will take part. The goal is to find the best dose and see if the drug shrinks tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CLCC F.Baclesse Caen
Caen, France
-
Gustave Roussy
Villejuif, France
-
Institut Curie
Paris, 75005, France
-
Institut de Cancerologie de l'Ouest- ICO
Saint-Herblain, 44805, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a High-Fiber diet shield the gut during breast cancer therapy?
- Can mapping tumor DNA unlock personalized breast cancer care?
- Can a Two-Pronged antibody boost Chemo's power against a tough breast cancer?
- Can a new drug rally the immune system against Hard-to-Treat cancers?
- Could an oral chemo pill improve breast cancer treatment?
- Can an immunotherapy cocktail slow pancreatic cancer? a new trial aims to find out.